Unique ID issued by UMIN | UMIN000005522 |
---|---|
Receipt number | R000002637 |
Scientific Title | Hypotensive effects of telmisartan 40mg/d with diuretics compared with telmisartan 80mg/d in hypertensive patients. |
Date of disclosure of the study information | 2011/04/28 |
Last modified on | 2011/04/28 10:42:11 |
Hypotensive effects of telmisartan 40mg/d with diuretics compared with telmisartan 80mg/d in hypertensive patients.
Hypotensive effects of telmisartan 40mg/d with diuretics compared with telmisartan 80mg/d in hypertensive patients.
Hypotensive effects of telmisartan 40mg/d with diuretics compared with telmisartan 80mg/d in hypertensive patients.
Hypotensive effects of telmisartan 40mg/d with diuretics compared with telmisartan 80mg/d in hypertensive patients.
Japan |
Hypertension
Medicine in general |
Others
NO
To evaluate hypotensive effects of telmisartan 40mg/d plus hyrdochlorothiazide 12.5mg/d or plus eplerenone 50mg/d or dose increase to telmisartan and metabolic syndrome who is not insufficient effect with telmisartan 40mg/d alone.
Bio-equivalence
Exploratory
Pragmatic
Not applicable
Systolic and diastolic blood pressure
home blood pressure, serum 1ipids, FBG, HbA1c, IRI, hsCRP, adipocytokine, plasma renin activity, plasma aldosterone
Interventional
Parallel
Randomized
Individual
Single blind -participants are blinded
Active
NO
NO
Institution is not considered as adjustment factor.
NO
Numbered container method
3
Treatment
Medicine |
Dose of telmisartan increased from 40mg/d to 80mg/d (6-month administration).
Hydrochlorothiazide 12.5mg/d add to telmisartan 40mg/d (6-month administration).
Eplerenone 50mg/d add to telmisartan 40mg/d (6-month administration).
20 | years-old | <= |
Not applicable |
Male and Female
1.Hypertensive patient who administrated telmisartan for three months or more, and still blood pressure is higher than Guideline target level. 2.Patient who have one or more metabolic syndorome risk factor (obesity,IGT etc.)
1. Pregnant or lactating women 2. Malignant hypertension and secondary hypertension 3. Diabetes mellitus patient with unstable glycemic control whose HbA1c is more than 8.0%, or complicated with diabetic nephropathy more than stage 2 4. Patient who is intoleramce or allergic aginst hydrochlorothiazide 5. FBG is more than 400mg/dL 6. patient who has kidney or liver dysfunction
75
1st name | |
Middle name | |
Last name | Yoshiyu Takeda |
Kanazawa University Hospital
Department of Endocrinology and Metabolism
13-1 takara-machi, Kanazawa, Japan
076-265-2252
1st name | |
Middle name | |
Last name | Yoshiyu Takeda |
Kanazawa University Hospital
Department of Endocrinology and Metabolism
13-1 takara-machi, Kanazawa, Japan
076-265-2252
takeday@med.kanazawa-u.ac.jp
Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University
None
Self funding
NO
金沢大学附属病院(石川県)
2011 | Year | 04 | Month | 28 | Day |
Partially published
Preinitiation
2011 | Year | 04 | Month | 28 | Day |
2011 | Year | 05 | Month | 01 | Day |
2013 | Year | 04 | Month | 01 | Day |
2013 | Year | 05 | Month | 01 | Day |
2011 | Year | 04 | Month | 28 | Day |
2011 | Year | 04 | Month | 28 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002637
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |